National Human Genome Research Institute Refocuses Extramural Research
The National Institutes of Healths National Human Genome Research Institute (NHGRI) is restructuring its extramural research program and making other organizational changes to accelerate the application of genomics to medicine.
The National Institutes of Health’s National Human Genome Research Institute (NHGRI) is restructuring its extramural research program and making other organizational changes to accelerate the application of genomics to medicine.
The reorganization, announced on Sept. 10, splits NHGRI’s extramural research unit into four new divisions. The Division of Genome Sciences will fund basic genomics research, technology development, and large-scale sequencing efforts; the Division of Genomic Medicine will focus on applying genomics to medicine and clinical care; the Division of Genomics & Society will oversee an expanded effort to understand the ethical, legal, and social implications of genomics; and the Division of Extramural Operations will manage grant administration and reviews.
“This reorganization reflects the expanding scope of genomics research, as described in NHGRI’s new strategic vision published in Nature last year,” NHGRI Director Eric D. Green says. “The mission of the institute has dramatically evolved from the singular focus on the Human Genome Project, for which NHGRI was created, to pursuing an exciting and broad set of opportunities for using genomics to advance medical science and improve human health.”
As part of the reorganization, two additional divisions—the Division of Policy, Communications & Education and the Division of Management—will be created from programs currently housed under the institute director’s office. The institute’s Division of Intramural Research will not undergo any changes. The reorganization will become effective on Oct. 1.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance